111 related articles for article (PubMed ID: 11376967)
1. Determination of the partition coefficients of a homologous series of ciprofloxacin: influence of the N-4 piperazinyl alkylation on the antimicrobial activity.
Vázquez JL; Merino S; Domenech O; Berlanga M; Viñas M; Montero MT; Hernández-Borrell J
Int J Pharm; 2001 Jun; 220(1-2):53-62. PubMed ID: 11376967
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and in vitro antibacterial activity of some N-(5-aryl-1,3,4-thiadiazole-2-yl)piperazinyl quinolone derivatives.
Foroumadi A; Soltani F; Moshafi MH; Ashraf-Askari R
Farmaco; 2003 Oct; 58(10):1023-8. PubMed ID: 14505733
[TBL] [Abstract][Full Text] [Related]
3. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC
J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of difloxacin against canine bacterial isolates.
van den Hoven R; Wagenaar JA; Walker RD
J Vet Diagn Invest; 2000 May; 12(3):218-23. PubMed ID: 10826834
[TBL] [Abstract][Full Text] [Related]
5. Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration.
Pendland SL; Neuhauser MM; Garey KW; Prause JL; Jung R
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):59-61. PubMed ID: 12376032
[TBL] [Abstract][Full Text] [Related]
6. [Nationwide sensitivity surveillance of ciprofloxacin and various parenteral antibiotics against bacteria isolated from patients with severe infections--the first Ciproxan IV special investigation in 2001].
Yamaguchi K; Ishii Y; Iinuma Y; Yamanaka K; Ichiyama S; Watanabe N; Uehara N; Kaku M; Kurokawa Y; Hayashi M; Hirakata Y
Jpn J Antibiot; 2003 Dec; 56(6):546-73. PubMed ID: 15007872
[TBL] [Abstract][Full Text] [Related]
7. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
Montanari MP; Mingoia M; Varaldo PE
Antimicrob Agents Chemother; 2001 Dec; 45(12):3616-22. PubMed ID: 11709353
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of 2-Furyl[(4-aralkyl)-1-piperazinyl]methanone derivatives as suitable antibacterial agents with mild cytotoxicity.
Abbasi MA; Nazeer MM; Rehman A; Siddiqui SZ; Hussain G; Shah SA; Ahmad I; Shahid M; Sarwar MS
Pak J Pharm Sci; 2018 Nov; 31(6):2477-2485. PubMed ID: 30473521
[TBL] [Abstract][Full Text] [Related]
9. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
Barry AL; Fuchs PC
J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria.
Moros M; Coll R; Esteve M; Parés J; Xicota MA
Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373
[No Abstract] [Full Text] [Related]
11. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Malmborg AS; Ahlén S
Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
[TBL] [Abstract][Full Text] [Related]
12. Comparative antimicrobial activity and spectrum of CP-99,219, a novel fluoroquinolone, tested against ciprofloxacin-resistant clinical isolates.
Murphy SP; Cormican MG; Jones RN
Ir J Med Sci; 1995; 164(4):271-3. PubMed ID: 8522427
[TBL] [Abstract][Full Text] [Related]
13. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
[TBL] [Abstract][Full Text] [Related]
14. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and antibacterial activity of N-[2-(5-bromothiophen-2-yl)-2-oxoethyl] and N-[(2-5-bromothiophen-2-yl)-2-oximinoethyl] derivatives of piperazinyl quinolones.
Foroumadi A; Emami S; Mehni M; Moshafi MH; Shafiee A
Bioorg Med Chem Lett; 2005 Oct; 15(20):4536-9. PubMed ID: 16115766
[TBL] [Abstract][Full Text] [Related]
16. [In vitro and in vivo antibacterial activities of a new quinolone derivative, FD501].
Imamori K; Asaoka T; Matsumoto M; Maebashi K; Matsuda H; Tahara Y
Jpn J Antibiot; 1996 Mar; 49(3):264-72. PubMed ID: 8935122
[TBL] [Abstract][Full Text] [Related]
17. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
Noviello S; Ianniello F; Leone S; Esposito S
Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
[TBL] [Abstract][Full Text] [Related]
18. Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies.
Cohen MA; Huband MD; Yoder SL; Gage JW; Roland GE
J Antimicrob Chemother; 1998 Jun; 41(6):605-14. PubMed ID: 9687098
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro evaluation of 2-(((2-ether)amino)methylene)-dimedone derivatives as potential antimicrobial agents.
Lone AM; Rather MA; Bhat MA; Bhat ZS; Tantry IQ; Prakash P
Microb Pathog; 2018 Jan; 114():431-435. PubMed ID: 29233781
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, antimycobacterial and antibacterial activity of ciprofloxacin derivatives containing a N-substituted benzyl moiety.
Wang S; Jia XD; Liu ML; Lu Y; Guo HY
Bioorg Med Chem Lett; 2012 Sep; 22(18):5971-5. PubMed ID: 22884110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
